Female DVIU and Urethral Dilation
Urethral dilation and direct vision internal urethrotomy (DVIU) are the two endoscopic options for female urethral stricture (FUS). Both open the lumen without excising scar, both are low-morbidity, and both have poor durability — the AUA 2023 guideline recommends offering urethroplasty over repeated endoscopic management once a stricture has been treated and recurred.[1] The female literature consistently groups dilation and DVIU together as "endoscopic management"; data isolating DVIU outcomes from dilation are extremely limited.[2][3][4]
For the male counterpart, see DVIU and Urethral Dilation. For paclitaxel-enhanced endoscopic treatment, see Drug-Coated Balloon Therapy.
Guideline Position
The AUA 2023 Urethral Stricture Disease Guideline Amendment addresses females explicitly, although the evidence base remains primarily male:[1]
| Scenario | AUA-Relevant Guidance |
|---|---|
| Initial endoscopic treatment of an FUS | Dilation and DVIU may be used interchangeably (Conditional, Grade C) |
| Catheter duration after dilation / DVIU | 24–72 h is reasonable; no benefit beyond 72 h |
| Self-catheterization adjunct | CIC after DVIU may reduce recurrence, particularly when continued > 4 months |
| Recurrent FUS after failed endoscopic treatment | Offer urethroplasty instead of repeated endoscopic management (Moderate, Grade C) — endoscopic re-treatment failure rates exceed 80% |
Why Female Strictures Are Different
FUS is rare — affecting roughly 4–20% of women evaluated for refractory LUTS-related bladder outlet obstruction.[2] No randomized trials exist; all evidence consists of retrospective case series with no standardized definition, diagnostic criteria, or outcome measures.[2][3]
Etiology is most commonly iatrogenic — repeated traumatic catheterization or serial dilation leading to fibrosis. Other causes include obstetric trauma (especially cephalopelvic disproportion), pelvic trauma, malignancy, radiation, urethral / vaginal atrophy, recurrent infection, and dermatologic disease (lichen planus, lichen sclerosus).[1]
Diagnosis is challenging given the non-specific presentation. Patients may report obstructive LUTS, recurrent UTI, hesitancy, weak stream, urgency-frequency, urethral pain, elevated PVR, or acute retention. Inability to pass even a small catheter is suggestive. VCUG demonstrates the entire female urethra well; cystourethroscopy confirms the stricture.[1]
Anatomic constraints unique to the female urethra:
- Short urethral length (~ 4 cm) — leaves less margin between the stricture and the sphincteric complex, raising the risk of de novo SUI with aggressive incision or dilation.
- DVIU is typically reserved for short, focal, distal-urethral or meatal strictures to keep the incision well below the rhabdosphincter.
- The risk-benefit balance for endoscopy is therefore narrower than in men.
Urethral Dilation
Dilation is the most commonly performed first-line endoscopic intervention for FUS, often attempted at least once before considering urethroplasty.[3][4]
Technique — sequential calibrated dilators (sounds or balloon dilators) progressively enlarge the lumen, typically to a target caliber of 24–30 Fr, performed in clinic or under anesthesia.
Outcomes — long-term success is consistently poor across systematic reviews:
| Series / Review | n | Mean follow-up | Pooled / reported success |
|---|---|---|---|
| Osman 2013 SR[5] | aggregated | 32–43 mo | ~ 47% |
| Sarin 2021 SR / meta[6] | aggregated | comparable | 41–49% pooled |
| Chakraborty 2022 review[4] | aggregated | comparable | 41–49% |
| Blaivas 2012[7] | 17 (initial dilation) | — | 6% durable success (16 / 17 recurred) |
| Bouchard 2025 review[3] | aggregated | — | efficacy decreases with each subsequent dilation |
Female DVIU
DVIU involves endoscopic incision of the stricture under direct vision, typically with cold knife. The 12 o'clock incision is often preferred to keep the cut away from the vaginal wall, although individual surgeons vary.
Technical considerations specific to the female urethra:
- The short urethra means even a "short" incision approaches the sphincter; incise conservatively.
- DVIU is most appropriate for short, focal strictures, particularly meatal or distal.
- Standalone female-DVIU outcome data are scarce — most series pool DVIU with dilation under "endoscopic management."[2][5][8]
Endoscopic Management vs Urethroplasty
All forms of female urethroplasty substantially outperform endoscopic management:
| Technique | Pooled success | Mean follow-up |
|---|---|---|
| Urethral dilation / DVIU | 41–49% | 32–43 mo[4][5][6] |
| Vaginal flap urethroplasty | 91–93% | 32–42 mo[4][5][6] |
| Buccal mucosa graft urethroplasty | 89–94% | 15–19 mo[5][6] |
| Vaginal free graft urethroplasty | 80–87% | 15–22 mo[5][6] |
The consensus across the literature is that urethroplasty should not be delayed after failure or short-interval recurrence following dilation or DVIU; most experts recommend proceeding to urethroplasty after one or at most two failed endoscopic attempts.[3][4][8]
Drug-Coated Balloon — Where the Female Evidence Stands
Optilume drug-coated balloon (DCB) is FDA-approved for anterior urethral stricture in men. The female evidence base is very small and very poor — currently two case reports plus a single 12-patient single-center conference abstract. Use should be considered exploratory and individualized; counsel accordingly.[9][10][11]
Complications and Adjuncts
- Recurrence is the dominant complication; risk rises with each repeat endoscopic attempt.
- De novo SUI is the major procedure-specific concern, particularly with aggressive dilation or DVIU near the sphincter; reported more commonly after open urethroplasty (~ 9.4% mild-to-moderate, most responsive to PFPT) than after endoscopic treatment.[3]
- Other complications: urethral bleeding, false passage, worsening peri-urethral fibrosis. Repeat instrumentation itself is a recognized cause of stricture progression.[1]
- CIC adjunct — clean intermittent self-catheterization after DVIU may reduce recurrence; benefit is most consistent when continued > 4 months.[1]
- Intralesional injection of mitomycin C or corticosteroids at the time of DVIU has been described, with limited evidence in females.[1]
Summary
Female urethral dilation and DVIU remain the initial endoscopic options for FUS due to simplicity and low morbidity, but long-term success is approximately 41–49% — substantially below the 80–94% durability of urethroplasty (vaginal flap, BMG, vaginal graft). The AUA 2023 guideline and contemporary reviews converge on the same operational rule: proceed to urethroplasty after one or at most two failed endoscopic attempts rather than subjecting the patient to repeated dilation.[1][3][4][5][6][8]
References
1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.
2. Turchi B, Lumen N, Verla W, Waterloos M. Female urethral stricture disease: a narrative review on diagnosis, surgical techniques and outcomes. Int J Impot Res. 2026;38(4):286-295. doi:10.1038/s41443-025-01079-6.
3. Bouchard B, Campeau L. Surgery for female urethral stricture. Neurourol Urodyn. 2025;44(1):51-62. doi:10.1002/nau.25358.
4. Chakraborty JN, Chawla A, Vyas N. Surgical interventions in female urethral strictures: a comprehensive literature review. Int Urogynecol J. 2022;33(3):459-485. doi:10.1007/s00192-021-04906-8.
5. Osman NI, Mangera A, Chapple CR. A systematic review of surgical techniques used in the treatment of female urethral stricture. Eur Urol. 2013;64(6):965-973. doi:10.1016/j.eururo.2013.07.038.
6. Sarin I, Narain TA, Panwar VK, et al. Deciphering the enigma of female urethral strictures: a systematic review and meta-analysis of management modalities. Neurourol Urodyn. 2021;40(1):65-79. doi:10.1002/nau.24584.
7. Blaivas JG, Santos JA, Tsui JF, et al. Management of urethral stricture in women. J Urol. 2012;188(5):1778-1782. doi:10.1016/j.juro.2012.07.042.
8. Waterloos M, Verla W. Female urethroplasty: a practical guide emphasizing diagnosis and surgical treatment of female urethral stricture disease. Biomed Res Int. 2019;2019:6715257. doi:10.1155/2019/6715257.
9. Stuehmeier J, Jelisejevas LA, Kink P, Gulacsi A, Horninger W, Rehder P. Optilume drug-coated balloon dilation in complex female urethral stricture. Urol Case Rep. 2021;41:101987. doi:10.1016/j.eucr.2021.101987.
10. Jelisejevas LA, Tulchiner G, Stuehmeier J, et al. PD05-02 Optilume drug-coated balloon dilation in the treatment of female urethral stricture disease. J Urol. 2025;213(5S):e108. doi:10.1097/01.JU.0001109760.63452.97.02.
11. Thomas HS, Stern N, Neu S, Herschorn S. Drug-coated balloon dilation for female urethral stricture. Urol Case Rep. 2025;59:102985. doi:10.1016/j.eucr.2025.102985.